Linsidomine
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Linsidomine (3-morpholinosydnonimine or SIN-1[1]) is a vasodilator. It is a metabolite of the antianginal drug molsidomine and acts by releasing NO from the endothelial cells nonenzymatically. It also hyperpolarizes the cell membrane through influencing the sodium-potassium pump and thereby rendering it less responsive to adrenergic stimulation. Linsidomine injection at a dose of 1 mg produces usable erection in about 70% of patients and full erection in up to 50% of patients. Linsidomine does not appear to be associated with priapism.
Linsidomine is neurotoxic and promotes oxidative stress on neurons.[2] Linsidomine is a peroxynitrite-generating compound involved in the pathogenesis of neurodegenerative diseases.[3]
References
References
- ↑ Wen, TC.; Rogido, MR.; Moore, JE.; Genetta, T.; Peng, H.; Sola, A. (Oct 2005). “Cardiotrophin-1 protects cortical neuronal cells against free radical-induced injuries in vitro”. Neurosci Lett. 387 (1): 38–42. doi:10.1016/j.neulet.2005.07.018. PMID 16084018.
- ↑ Wallace, DR.; Dodson, S.; Nath, A.; Booze, RM. (Jan 2006). “Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function”. Synapse. 59 (1): 51–60. doi:10.1002/syn.20214. PMID 16237680.
- ↑ Jang, JH.; Aruoma, OI.; Jen, LS.; Chung, HY.; Surh, YJ. (Feb 2004). “Ergothioneine rescues PC12 cells from beta-amyloid-induced apoptotic death”. Free Radic Biol Med. 36 (3): 288–99. doi:10.1016/j.freeradbiomed.2003.11.005. PMID 15036348.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH